Close Menu

NEW YORK – New study results have confirmed that advanced melanoma patients treated with a combination of molecularly targeted drugs appear to see significant benefit from this approach compared to what would be expected based on data from older studies of non-targeted treatment.

The new evidence, from a five-year outcomes analysis of a prospective clinical trial, adds to growing affirmation of the positive impact of precision medicine, at least for certain subsets of cancer patients. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.